Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Terran Biosciences Announces New Breakthroughs in the Chemistry of MDMA
Terran Biosciences, a biotech platform company dedicated to the development of transformational therapeutics for neurological […]
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
Dyne Therapeutics, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people […]
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Takeda and HUTCHMED have announced that the U.S. Food and Drug Administration (“FDA”) has granted […]
Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004
Lynk Pharmaceuticals, an innovative clinical stage company, announced that it has dosed the first cohort […]
TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion
TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, […]
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
INOVIO, a biotechnology company focused on developing and commercializing DNA medicines to help treat and […]
bit.bio Launches New Custom Disease Model Cells Offering, Advancing Disease Research and Drug Discovery
bit.bio, a cell coding company, has launched its new Custom ioDisease Model Cells offering. This […]
FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria
The U.S. Food and Drug Administration (FDA) has approved Xacduro (sulbactam for injection; durlobactam for […]
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
Vega Therapeutics, a clinical-stage biotechnology company developing novel therapies for rare blood disorders, today announced […]
Antengene Announces Antibody-Drug Conjugate Granted Orphan Drug Designations by the FDA for the Treatment of Gastric and Pancreatic Cancers
Antengene Corporation, a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more